Emmanuel H Demont

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1104337/publications.pdf

Version: 2024-02-01

38 papers	1,855 citations	257357 24 h-index	315616 38 g-index
40 all docs	40 docs citations	40 times ranked	1837 citing authors

#	Article	IF	Citations
1	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science, 2020, 368, 387-394.	6.0	274
2	Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases ?-cleavage of amyloid precursor protein and amyloid-? production in vivo. Journal of Neurochemistry, 2007, 100, 802-809.	2.1	186
3	The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 8111-8131.	2.9	159
4	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. Journal of Medicinal Chemistry, 2018, 61, 4317-4334.	2.9	94
5	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 6151-6178.	2.9	81
6	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 5649-5673.	2.9	75
7	A Chemical Probe for the ATAD2 Bromodomain. Angewandte Chemie - International Edition, 2016, 55, 11382-11386.	7.2	67
8	BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1022-1026.	1.0	62
9	Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability. Journal of Medicinal Chemistry, 2008, 51, 3313-3317.	2.9	62
10	GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins. Journal of Medicinal Chemistry, 2020, 63, 9045-9069.	2.9	59
11	BACE-1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1017-1021.	1.0	55
12	Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3674-3678.	1.0	53
13	Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3664-3668.	1.0	46
14	BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs). Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1011-1016.	1.0	45
15	Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3669-3673.	1.0	45
16	Domain-selective targeting of BET proteins in cancer and immunological diseases. Current Opinion in Chemical Biology, 2020, 57, 184-193.	2.8	43
17	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 9093-9126.	2.9	41
18	Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. Journal of Medicinal Chemistry, 2020, 63, 9070-9092.	2.9	40

#	Article	IF	Citations
19	Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. Journal of Medicinal Chemistry, 2020, 63, 9020-9044.	2.9	38
20	Discovery of a Brain-Penetrant S1P₃-Sparing Direct Agonist of the S1P₁ and S1P₅ Receptors Efficacious at Low Oral Dose. Journal of Medicinal Chemistry, 2011, 54, 6724-6733.	2.9	31
21	Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit. Journal of Medicinal Chemistry, 2021, 64, 10806-10833.	2.9	31
22	Discovery of a Selective S1P₁ Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate. ACS Medicinal Chemistry Letters, 2011, 2, 444-449.	1.3	27
23	Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression. Journal of Medicinal Chemistry, 2021, 64, 12200-12227.	2.9	26
24	GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family. ACS Medicinal Chemistry Letters, 2020, 11, 1581-1587.	1.3	25
25	Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles. Journal of Medicinal Chemistry, 2014, 57, 10424-10442.	2.9	19
26	A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification. Journal of Medicinal Chemistry, 2019, 62, 7506-7525.	2.9	19
27	Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 3249-3281.	2.9	19
28	Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 8321-8336.	2.9	17
29	Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10711-10741.	2.9	17
30	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10772-10805.	2.9	17
31	Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P₁ Agonists. Journal of Medicinal Chemistry, 2015, 58, 8236-8256.	2.9	15
32	Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode. Journal of Medicinal Chemistry, 2020, 63, 5212-5241.	2.9	14
33	Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins. Journal of Medicinal Chemistry, 2021, 64, 10742-10771.	2.9	14
34	BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4639-4644.	1.0	12
35	A Chemical Probe for the ATAD2 Bromodomain. Angewandte Chemie, 2016, 128, 11554-11558.	1.6	10
36	Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P₃)-Sparing S1P₁ Agonists Active at Low Oral Doses. Journal of Medicinal Chemistry, 2016, 59, 1003-1020.	2.9	10

#	Article	IF	Citations
37	Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1308-1317.	1.3	4
38	Multigram Synthesis of Tetrasubstituted Dihydrobenzofuran GSK973 Enabled by High-Throughput Experimentation and a Claisen Rearrangement in Flow. Organic Process Research and Development, 2022, 26, 365-379.	1.3	2